Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate TScan Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding TScan Therapeutics, Inc.’s stock price such as:

• TScan Therapeutics, Inc.’s current stock price and volume
• Why TScan Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TCRX from analysts
• TCRX’s stock price momentum as measured by its relative strength

About TScan Therapeutics, Inc. (TCRX)

Before we jump into TScan Therapeutics, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Want to learn more about TScan Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about TScan Therapeutics, Inc..

TScan Therapeutics, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, TScan Therapeutics, Inc.’s stock price was $1.110.

TScan Therapeutics, Inc. is 0% from its previous closing price of $1.110.

During the last market session, TScan Therapeutics, Inc.’s stock traded between $1.065 and $1.190. Currently, there are approximately 56.75 million shares outstanding for TScan Therapeutics, Inc..

TScan Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

TScan Therapeutics, Inc. Stock Price History

TScan Therapeutics, Inc.’s (TCRX) price is currently down 42.78% so far this month.

During the month of November, TScan Therapeutics, Inc.’s stock price has reached a high of $1.480 and a low of $0.910.

Over the last year, TScan Therapeutics, Inc. has hit prices as high as $4.940 and as low as $0.910. Year to date, TScan Therapeutics, Inc.’s stock is down 63.49%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused TScan Therapeutics, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were 0 analysts who downgraded TScan Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate TScan Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on TScan Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

TScan Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about TScan Therapeutics, Inc. (TCRX) by visiting AAII Stock Evaluator.

Relative Price Strength of TScan Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, TScan Therapeutics, Inc. has a weighted four-quarter relative price strength of -30.30%, which translates to a Momentum Score of 4 and is considered to be Very Weak.

Want to learn more about how TScan Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

TScan Therapeutics, Inc. Stock Price: Bottom Line

As of November 28, 2025, TScan Therapeutics, Inc.’s stock price is $1.110, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like TScan Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.